BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference

Rhea-AI Summary

BrainsWay, a leader in advanced non-invasive treatments for brain disorders, announced that CEO Christopher von Jako will participate in a virtual fireside chat at the H.C. Wainwright Annual Global Investment Conference on September 12, 2022. The event will take place at the Lotte Palace Hotel in New York City. The fireside chat is scheduled for 7:00 a.m. ET. BrainsWay is known for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology, which is FDA cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

BURLINGTON, Mass. and JERUSALEM, Aug. 31, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced and non-invasive treatment for brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Annual Global Investment Conference being held at the Lotte Palace Hotel in New York City on September 12-14, 2022. Presentation details below:

H.C. Wainwright Annual Global Investment Conference

Presentation Format:	Fireside Chat On-Demand
Date:	September 12, 2022
Time:	7:00 a.m. ET

Management will also meet with investors during the event. Investors interested in meeting with the BrainsWay management team during the conferences should contact their H.C. Wainwright representative.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.BrainsWay.com.

Contacts:
BrainsWay:
Scott Areglado
SVP and Chief Financial Officer
844-386-7001
Scott.Areglado@BrainsWay.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

What is BrainsWay's participation in the H.C. Wainwright Annual Global Investment Conference?

BrainsWay will have CEO Christopher von Jako participate in a virtual fireside chat on September 12, 2022, at 7:00 a.m. ET.

When is the H.C. Wainwright Annual Global Investment Conference taking place?

The conference will be held from September 12 to 14, 2022, at the Lotte Palace Hotel in New York City.

What technology does BrainsWay use for treating brain disorders?

BrainsWay uses the Deep Transcranial Magnetic Stimulation (Deep TMS™) platform, which is FDA cleared for several mental health disorders.

What disorders are treated by BrainsWay's Deep TMS technology?

Deep TMS is FDA cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

Who should investors contact to meet with BrainsWay management during the conference?

Investors interested in meetings should contact their H.C. Wainwright representative.